Ixekizumab | Anti-IL-17A, IL-17A/F | Therapeutic Monoclonal Antibody

Aliquoted from the original drug | Now available for research use

Aliquots of the reference drug Ixekizumab are now available as research consumables.

Ixekizumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.

Not looking for Ixekizumab Reference drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Taltz® / Ixekizumab Reference Product

Drug nameTaltz®
INNIxekizumab
API typeIxekizumab is a monoclonal antibody, produced in CHO cells by recombinant DNA technology.
Pharmacotherapeutic group
Immunosuppressants, interleukin inhibitors
ATC code
L04AC13
Target of antibody
17A (both IL-17A and IL-17A/F)
General functionIxekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (< 3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F). Elevated concentrations of IL-17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis and axial spondyloarthritis by driving inflammation leading to erosive bone damage and pathological new bone formation. Neutralisation of IL-17A by Ixekizumab inhibits these actions. Ixekizumab does not bind to ligands IL-17B, IL-17C, IL-17D, IL-17E or IL-17F.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Ixekizumab modulates biological responses that are induced or regulated by IL-17A. Based on psoriatic skin biopsy data from a phase I study, there was a dose-related trend toward decreased epidermal thickness, a number of proliferating keratinocytes, T cells, and dendritic cells, as well as reductions in local inflammatory markers from baseline to day 43. As a direct consequence of treatment with Ixekizumab reduces erythema, induration and desquamation present in plaque psoriasis lesions.
Original license holder
Eli Lilly and Company (Ireland) Limited
Dunderrow
Kinsale
Co. Cork
Ireland
Marketing authorisation numbers
EU/1/15/1085/001
EU/1/15/1085/002
EU/1/15/1085/003
Marketing authorisation holder
Eli Lilly and Company (Ireland) Limited
Dunderrow
Kinsale
Co. Cork
Ireland
Name of the manufacturer of the biological active substance
Eli Lilly Kinsale (Ireland) Limited
Dunderrow
Kinsale
Co. Cork
Ireland
Name and address of the manufacturer(s) responsible for batch releaseEli Lilly Italia S.p.A.
Via Gramsci 731/733
50019 Sesto Fiorentino (FI)
Italy
Max shelf life
2 years
Storage conditions
2°C – 8°C
List of excipients
Sucrose
Polysorbate 80
Water for injections
Sodium hydroxide may be used to adjust pH

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting